Inovio Pharma (INO) Misses Q3 EPS by 14c
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.15 +5.50%
Financial Fact:
License fee and milestone revenue from affiliated entity: 574.6K
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
License fee and milestone revenue from affiliated entity: 574.6K
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q3 EPS of ($0.39), $0.14 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $9.36 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- BofA Securities Downgrades Autohome Inc. (ATHM) to Underperform
- Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
